Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RCKT 21.98 -0.12(-0.54%)
Will RCKT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RCKT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RCKT
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
RCKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?
Other News for RCKT
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT)
Baron Health Care Fund Q1 2024 Shareholder Letter
RCKT Crosses Below Key Moving Average Level
Optimistic Buy Rating for Rocket Pharmaceuticals Based on Strong Gene Therapy Pipeline and Expert Leadership
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)